$1.52
-0.06-3.8%
Last update: Nov 10, 4:00 PM
BioLine Rx Ltd
BLRXNASDAQ
BioLine Rx fell 55.0% from $3.51 to $1.58, behind the S&P 500's +9.8%. Its worst day was Mar 23 (−11.5%), and its low came Nov 9 at $1.58.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.22 beat the $-0.49 estimate on $427,000.00 revenue (est. $606,000.00).
+3.2% · S&P 500 +1.5%
EPS of $-0.34 beat the $-0.54 estimate on $194,000.00 revenue (est. $651,598.00).
Story events cover the past 12 months · Times ET
−11.5%, the year's worst day · S&P 500 +1.1%
BioLine Rx shares rose 16.7%, while the S&P 500 fell 0.0%.
+16.7%, the year's best day · S&P 500 0.0%
EPS of $0.00 beat the $-1.04 estimate on $477,000.00 revenue (est. $343,000.00).
+5.6% · S&P 500 0.0%
EPS of $0.00 beat the $-0.24 estimate on $294,000.00 revenue (est. $500,000.00).
+9.4% · S&P 500 −0.3%
Where it ended: a close of $1.58 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.69, revenue est. $358,000.00).
Nothing in the past 12 months.
All BLRX analyst actionsNothing in the past 12 months.
All BLRX dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BLRX and SPY from Benzinga historical bars. Not investment advice.
